Home

Subscribe | Sian In

ETPrime Markets News Industry RISE Politics Wealth MF Tech Jobs Opinion NRI Panache ET NOW More Auto ▼ Banking/Finance ▼ Cons. Products ▼ Energy ▼ Ind'l Goods/Svs ▼ Healthcare/Biotech ▼ Services ▼ Media/Entertainment ▼ Transportation ▼ More ▼

Business News > Industry > Healthcare/Biotech > Pharmaceuticals > Large pharma companies back appeal for TRIPS waiver for Covid-19 cure

Large pharma companies back appeal for TRIPS waiver for Covid-19 cure

By Divya Rajagopal, ET Bureau

Last Updated: Oct 05, 2020, 06:58 AM IST

FONT SIZE SAVE

PRINT COMMENT

Synopsis

"We endorse the Indian government's stand asking for a waiver of the TRIPS provisions to deal with the Covid-19 crisis. This is the time for solidarity and global cooperation," Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, told ET on Sunday.



ge Indian cos told the govt that when companies are willing to offer voluntary licences, waiver of IP should not be demanded.

MUMBAI: A lobby group of large Indian drug companies has endorsed the Indian government's appeal to the World Trade Organization to waive certain provisions of Trade Related Intellectual Property Rights (TRIPS) for Covid-19 therapeutics, including vaccines. However, they said such rights should be respected when there is voluntary licensing, where patent

holders grant permits to drug makers to produce medicines at affordable levels.

"We endorse the Indian government's stand asking for a waiver of the TRIPS provisions to deal with the Covid-19 crisis. This is the time for solidarity and global cooperation," Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, told ET on Sunday.

Indian drug companies stepped up to supply drugs such as hydroxychloroquine and paracetamol soon after the Covid-19 outbreak and they are ready to do so now to make vaccines for the world, Jain added.

The commerce ministry invited comments from industry associations on this issue a few weeks ago, officials aware of the development told ET. Large Indian companies, ET has learnt, told the government that when companies are willing to offer voluntary licences, waiver of IP should not be demanded.

"Wherever there are voluntary licensing agreements with Indian companies, it should be respected, but if companies are hoarding a certain drug or vaccine and the access to these treatments is blocked, then these exemptions need to

IN THE SPOTLIGHT F-series on Flipkart! Are you ready for this big party?



be introduced," said an official aware of the matter.

Two patented Covid-19 drugs are now available in India – the experimental remdesivir from <u>Gilead Sciences</u> of the US and tocilizumab by Swiss drug maker Roche. Gilead granted licences to seven Indian drug manufacturers, while Roche has a marketing tie-up with <u>Cipla</u> NSE 2.06 %.

Still, some drug makers that are not part of voluntary licensing deals have complained that access to lifesaving Covid-19 therapies is being held back because of restrictive licensing.

For vaccines, the <u>Serum Institute of India</u> has tie-ups with <u>AstraZeneca</u> <u>NSE 0.42 %</u> and Novavax; Biological E has a manufacturing accord with US drug maker Johnson & Johnson and Dr Reddy's Laboratories has signed up with Russian Direct Investment Fund, the sovereign wealth fund supporting the development of the Sputnik-V vaccine. "This is going to be a test case and this debate about waiver will take significance when Covid-19 vaccines come in," the official said.

The IPA's statement came days after India and South Africa jointly asked the WTO to waive certain TRIPS provisions for the prevention, containment and treatment of Covid-19.

India and South Africa said it is important for WTO members to work together to ensure that IP rights such as patents, industrial designs, copyright and protection of undisclosed information do not create barriers to the timely access to affordable medical products or to the scaling-up of research, development, manufacturing and supply of medical products essential to combat Covid-19.


India and South Africa have sought a two-year waiver of certain IP provisions for Covid-19 therapies, ET has learnt.

READ MORE NEWS ON Gilead Sciences Trade Related Intellectual Property Rights Novavax Serum Institute Of India Cipla Astrazeneca World Trade Organization

(Catch all the <u>Business News</u>, <u>Breaking News</u> Events and <u>Latest News</u> Updates on <u>The Economic Times</u>.)

Download <u>The Economic Times News App</u> to get Daily Market Updates & Live Business News.

ADD COMMENT



Top Trending Industry Terms





Trending Now		Popular Categories			
Vodafone	Honor Smartphone	Auto B		Banking/Finance	
BigBasket	October Bank Holidays	Cons. Products Energy			
IRCTC News	Oxford Coronavirus Vaccine	Ind' Goods/Svs Healthca		are/Biotech	
Indian Navy News	IAF News	Services Media/En		ntertainment	
SpaceX	Netflix News	Transportation Tech			
Delhi Summers	Delhi Metro	Telecom Miscellar		neous	
Reliance Jio		CSR Environme		ment	
Hot On Web		In Case You Mis	ssed It		
Jio	Sensex today	Vodafone Idea Huawei			
Bank holidays in October 2020	Narendra Modi	Tata Group October		Bank Holidays	
US elections 2020	What are multi asset funds	Delhi Rains Russia Co		Covid Vaccine	
Kolkata explosion Live updates	What are balanced funds	Indian Navy News China Nev		ews	
Gold rate today	Global markets	AGR dues	R dues Auto New		
Best value funds to invest in 2020	Breaking news	Banking News	Jio Fibe		
YES Bank share price	SGX Nifty				
Sensex Live	IRCTC share price				
Infosys share price					
ET Verticals		More From Our Network			
Auto News	Retail News	इकनॉमिक टाइम्स	ઈકોનોમિક ટાઈમ્સ	Pune Mirror	
Health News	Telecom News	Bangalore Mirror	Ahmedabad Mirror	ItsMyAscent	
Energy News	IT News	Education Times	Brand Capital	Mumbai Mirror	
Real Estate News	Marketing & Advertising News	Times Now	Indiatimes	महाराष्ट्र टाइम्	
Technology News	CFO News	ವಿಜಯ ಕರ್ನಾಟಕ	Go Green	AdAge India	
IT Security News		Eisamay	IGN India	lamGujarat	
		Times of India	Samayam Tamil	Samayam Telugu	
		Miss Kyra	Bombay Times	Filmipop	
		MX Player	Newspaper	Times Prime	
			Subscription		
		Colombia	NBT Gold Podcast	Ei Samay Gold Podcas	
		MX ShareKaro App	MX TakaTak App		
Other Useful Links		Services			
About Us	Subscribe to ET Prime	Longwalks App			
Book your Newspaper Subscription	n Create Your Own Ad				
Advertise with Us	Terms of Use & Grievance Redressal				
Privacy policy	Contact Us				
RSS					
follow Us On: Do		SUBSCRIBE			

Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: <u>Times Syndication Service</u>

TO OUR NEWSLETTER